Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) EBITDA: 2021-2025

Historic EBITDA for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to -$12.7 million.

  • SAB Biotherapeutics' EBITDA fell 12.11% to -$12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.2 million, marking a year-over-year increase of 16.58%. This contributed to the annual value of -$42.9 million for FY2024, which is 12.70% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported EBITDA of -$12.7 million as of Q3 2025, which was down 30.28% from -$9.7 million recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year EBITDA high stood at $813,924 for Q1 2021, and its period low was -$18.9 million during Q4 2023.
  • Over the past 3 years, SAB Biotherapeutics' median EBITDA value was -$10.2 million (recorded in 2024), while the average stood at -$10.4 million.
  • In the last 5 years, SAB Biotherapeutics' EBITDA slumped by 924.07% in 2022 and then surged by 46.97% in 2024.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' EBITDA stood at -$7.3 million in 2021, then declined by 7.02% to -$7.9 million in 2022, then plummeted by 140.12% to -$18.9 million in 2023, then surged by 46.97% to -$10.0 million in 2024, then declined by 12.11% to -$12.7 million in 2025.
  • Its last three reported values are -$12.7 million in Q3 2025, -$9.7 million for Q2 2025, and -$10.8 million during Q1 2025.